Terms: = Leukemia AND BCL2, Bcl-2, 596, ENSG00000171791 AND Clinical Outcome
90 results:
1. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
[TBL] [Abstract] [Full Text] [Related]
2. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract] [Full Text] [Related]
3. PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
[TBL] [Abstract] [Full Text] [Related]
4. Mechanism of Action of Decitabine in the Treatment of Acute Myeloid leukemia by Regulating LINC00599.
Du F; Jin T; Wang L
Anal Cell Pathol (Amst); 2023; 2023():2951519. PubMed ID: 36874552
[TBL] [Abstract] [Full Text] [Related]
5. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Mongiorgi S; De Stefano A; Ratti S; Indio V; Astolfi A; Casalin I; Pellagatti A; Paolini S; Parisi S; Cavo M; Pession A; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L; Follo MY
Clin Epigenetics; 2023 Feb; 15(1):27. PubMed ID: 36803590
[TBL] [Abstract] [Full Text] [Related]
6. A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions.
Tolomeo D; Agostini A; Solimando AG; Cunsolo CL; Cimarosto L; Palumbo O; Palumbo P; Carella M; Hernández-Sánchez M; Hernández-Rivas JM; Storlazzi CT
Cancer Genet; 2023 Apr; 272-273():16-22. PubMed ID: 36641997
[TBL] [Abstract] [Full Text] [Related]
7. Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.
Tsuzuki H; Kawase T; Nakazawa T; Mori M; Yoshida T
Oncotarget; 2022 Dec; 13():1359-1368. PubMed ID: 36537913
[TBL] [Abstract] [Full Text] [Related]
8. bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma.
Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
[TBL] [Abstract] [Full Text] [Related]
9. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
10. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and bcl2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
11. An
Lin S; Larrue C; Scheidegger NK; Seong BKA; Dharia NV; Kuljanin M; Wechsler CS; Kugener G; Robichaud AL; Conway AS; Mashaka T; Mouche S; Adane B; Ryan JA; Mancias JD; Younger ST; Piccioni F; Lee LH; Wunderlich M; Letai A; Tamburini J; Stegmaier K
Cancer Discov; 2022 Feb; 12(2):432-449. PubMed ID: 34531254
[TBL] [Abstract] [Full Text] [Related]
12. CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.
Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
[TBL] [Abstract] [Full Text] [Related]
13. Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199.
Mao S; Ling Q; Pan J; Li F; Huang S; Ye W; Wei W; Lin X; Qian Y; Wang Y; Huang X; Huang J; Wang J; Jin J
J Transl Med; 2021 Apr; 19(1):181. PubMed ID: 33926484
[TBL] [Abstract] [Full Text] [Related]
14. Can Treatment with Venetoclax for Chronic Lymphocytic leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
Abdel-Samad N; Sughayar R
Am J Case Rep; 2021 Mar; 22():e928514. PubMed ID: 33750754
[TBL] [Abstract] [Full Text] [Related]
15. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
[TBL] [Abstract] [Full Text] [Related]
16. Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia.
Chen K; Yang Q; Zha J; Deng M; Zhou Y; Fu G; Bi S; Feng L; Xu-Monette ZY; Chen XL; Fu G; Dai Y; Young KH; Xu B
Cell Death Dis; 2020 Sep; 11(9):778. PubMed ID: 32948748
[TBL] [Abstract] [Full Text] [Related]
17. TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and bcl-2 inhibitors.
Morabito F; Gentile M; Monti P; Recchia AG; Menichini P; Skafi M; Atrash M; De Luca G; Bossio S; Al-Janazreh H; Galimberti S; Salah Z; Morabito L; Mujahed A; Hindiyeh M; Dono M; Fais F; Cutrona G; Neri A; Tripepi G; Fronza G; Ferrarini M
Expert Opin Investig Drugs; 2020 Aug; 29(8):869-880. PubMed ID: 32551999
[TBL] [Abstract] [Full Text] [Related]
18. FLI1 and MIC2 expression in precursor B-lymphoblastic leukemia with Burkitt-like morphology and extensive extramedullary involvement: A diagnostic challenge in pediatric small round cell tumor.
Das N; Thakral D; Singh G; Malhotra A; Phulware RH; Gogia A; Gupta R
Indian J Pathol Microbiol; 2019; 62(4):614-617. PubMed ID: 31611454
[TBL] [Abstract] [Full Text] [Related]
19. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
[TBL] [Abstract] [Full Text] [Related]
20. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
Saenz DT; Fiskus W; Manshouri T; Mill CP; Qian Y; Raina K; Rajapakshe K; Coarfa C; Soldi R; Bose P; Borthakur G; Kadia TM; Khoury JD; Masarova L; Nowak AJ; Sun B; Saenz DN; Kornblau SM; Horrigan S; Sharma S; Qiu P; Crews CM; Verstovsek S; Bhalla KN
Leukemia; 2019 Jun; 33(6):1373-1386. PubMed ID: 30575820
[TBL] [Abstract] [Full Text] [Related]
[Next]
